AGC Biologics, BioConnection forge partnership to be an alternative to WuXi

Two man­u­fac­tur­ers are join­ing forces to court bio­phar­ma com­pa­nies look­ing for ser­vice providers out­side of Chi­na.

CD­MO AGC Bi­o­log­ics and CMO Bio­Con­nec­tion said on Wednes­day they are part­ner­ing to of­fer clin­i­cal-stage man­u­fac­tur­ing for gene ther­a­pies. Com­pa­nies are search­ing for a “one-stop-shop so­lu­tion,” AGC Bio CBO Christoph Win­ter­hal­ter told End­points News in an in­ter­view.

But Win­ter­hal­ter al­so said that this col­lab­o­ra­tion can pro­vide the same ser­vices as WuXi Bi­o­log­ics, which has a sin­gle-use biore­ac­tor sys­tem just like Seat­tle, WA-based AGC Bio, but out­side of Chi­na. WuXi Bi­o­log­ics did not re­spond to re­quests for com­ment as of press time on Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.